vs

Side-by-side financial comparison of Amalgamated Financial Corp. (AMAL) and BICYCLE THERAPEUTICS PLC (BCYC). Click either name above to swap in a different company.

Amalgamated Financial Corp. is the larger business by last-quarter revenue ($85.2M vs $48.0M, roughly 1.8× BICYCLE THERAPEUTICS PLC). On growth, BICYCLE THERAPEUTICS PLC posted the faster year-over-year revenue change (1193.3% vs 9.4%). Amalgamated Financial Corp. produced more free cash flow last quarter ($134.4M vs $-19.9M). Over the past eight quarters, BICYCLE THERAPEUTICS PLC's revenue compounded faster (56.7% CAGR vs 4.3%).

CI Financial is a Canadian investment management company based in Toronto, Ontario. It offers investment management and wealth management services targeted to high net worth retail investors, as well as brokerage and trading services to portfolio managers and institutional investors.

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical firm developing innovative bicyclic peptide therapies for unmet medical needs. Its core pipeline covers oncology, rare diseases, and immunological disorders, with operations in Europe and North America, and partnerships with global pharma leaders to advance drug candidates to market.

AMAL vs BCYC — Head-to-Head

Bigger by revenue
AMAL
AMAL
1.8× larger
AMAL
$85.2M
$48.0M
BCYC
Growing faster (revenue YoY)
BCYC
BCYC
+1183.9% gap
BCYC
1193.3%
9.4%
AMAL
More free cash flow
AMAL
AMAL
$154.3M more FCF
AMAL
$134.4M
$-19.9M
BCYC
Faster 2-yr revenue CAGR
BCYC
BCYC
Annualised
BCYC
56.7%
4.3%
AMAL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AMAL
AMAL
BCYC
BCYC
Revenue
$85.2M
$48.0M
Net Profit
$-20.2M
Gross Margin
Operating Margin
39.0%
-51.5%
Net Margin
-42.0%
Revenue YoY
9.4%
1193.3%
Net Profit YoY
61.1%
EPS (diluted)
$0.88
$-0.29

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AMAL
AMAL
BCYC
BCYC
Q4 25
$85.2M
$48.0M
Q3 25
$85.6M
$11.7M
Q2 25
$80.9M
$2.9M
Q1 25
$77.0M
$10.0M
Q4 24
$77.9M
$3.7M
Q3 24
$81.0M
$2.7M
Q2 24
$78.5M
$9.4M
Q1 24
$78.3M
$19.5M
Net Profit
AMAL
AMAL
BCYC
BCYC
Q4 25
$-20.2M
Q3 25
$26.8M
$-59.1M
Q2 25
$26.0M
$-79.0M
Q1 25
$25.0M
$-60.8M
Q4 24
Q3 24
$27.9M
$-50.8M
Q2 24
$26.8M
$-39.8M
Q1 24
$27.2M
$-26.6M
Operating Margin
AMAL
AMAL
BCYC
BCYC
Q4 25
39.0%
-51.5%
Q3 25
42.9%
-558.6%
Q2 25
43.8%
-2965.8%
Q1 25
45.1%
-703.7%
Q4 24
42.4%
Q3 24
47.2%
-2385.9%
Q2 24
45.6%
-498.3%
Q1 24
49.2%
-162.4%
Net Margin
AMAL
AMAL
BCYC
BCYC
Q4 25
-42.0%
Q3 25
31.3%
-503.7%
Q2 25
32.1%
-2703.8%
Q1 25
32.5%
-608.9%
Q4 24
Q3 24
34.5%
-1898.4%
Q2 24
34.1%
-425.3%
Q1 24
34.8%
-136.0%
EPS (diluted)
AMAL
AMAL
BCYC
BCYC
Q4 25
$0.88
$-0.29
Q3 25
$0.88
$-0.85
Q2 25
$0.84
$-1.14
Q1 25
$0.81
$-0.88
Q4 24
$0.78
Q3 24
$0.90
$-0.74
Q2 24
$0.87
$-0.77
Q1 24
$0.89
$-0.62

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AMAL
AMAL
BCYC
BCYC
Cash + ST InvestmentsLiquidity on hand
$291.2M
$628.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$794.5M
$610.0M
Total Assets
$8.9B
$717.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AMAL
AMAL
BCYC
BCYC
Q4 25
$291.2M
$628.1M
Q3 25
$115.5M
$648.3M
Q2 25
$171.1M
$721.5M
Q1 25
$65.7M
$793.0M
Q4 24
$60.7M
$879.5M
Q3 24
$149.2M
$890.9M
Q2 24
$58.0M
$961.4M
Q1 24
$155.2M
$457.0M
Total Debt
AMAL
AMAL
BCYC
BCYC
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
$30.9M
Q1 24
$30.8M
Stockholders' Equity
AMAL
AMAL
BCYC
BCYC
Q4 25
$794.5M
$610.0M
Q3 25
$775.6M
$618.5M
Q2 25
$754.0M
$668.9M
Q1 25
$736.0M
$740.3M
Q4 24
$707.7M
$793.1M
Q3 24
$698.2M
$831.0M
Q2 24
$646.0M
$873.8M
Q1 24
$616.8M
$356.0M
Total Assets
AMAL
AMAL
BCYC
BCYC
Q4 25
$8.9B
$717.6M
Q3 25
$8.7B
$764.0M
Q2 25
$8.6B
$832.2M
Q1 25
$8.3B
$883.9M
Q4 24
$8.3B
$956.9M
Q3 24
$8.4B
$996.7M
Q2 24
$8.3B
$1.1B
Q1 24
$8.1B
$547.1M
Debt / Equity
AMAL
AMAL
BCYC
BCYC
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
0.04×
Q1 24
0.09×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AMAL
AMAL
BCYC
BCYC
Operating Cash FlowLast quarter
$135.8M
$-19.3M
Free Cash FlowOCF − Capex
$134.4M
$-19.9M
FCF MarginFCF / Revenue
157.8%
-41.5%
Capex IntensityCapex / Revenue
1.6%
1.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$229.4M
$-252.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AMAL
AMAL
BCYC
BCYC
Q4 25
$135.8M
$-19.3M
Q3 25
$39.5M
$-71.2M
Q2 25
$24.9M
$-72.8M
Q1 25
$34.2M
$-86.4M
Q4 24
$124.1M
$-164.7M
Q3 24
$35.8M
$-39.8M
Q2 24
$28.0M
$-44.6M
Q1 24
$31.3M
$-70.9M
Free Cash Flow
AMAL
AMAL
BCYC
BCYC
Q4 25
$134.4M
$-19.9M
Q3 25
$38.3M
$-71.8M
Q2 25
$24.2M
$-73.3M
Q1 25
$32.5M
$-87.0M
Q4 24
$122.3M
$-166.0M
Q3 24
$35.2M
$-40.3M
Q2 24
$27.8M
$-45.0M
Q1 24
$31.1M
$-70.9M
FCF Margin
AMAL
AMAL
BCYC
BCYC
Q4 25
157.8%
-41.5%
Q3 25
44.7%
-612.3%
Q2 25
29.9%
-2509.7%
Q1 25
42.2%
-871.7%
Q4 24
157.0%
-4475.7%
Q3 24
43.4%
-1504.7%
Q2 24
35.4%
-481.2%
Q1 24
39.7%
-362.9%
Capex Intensity
AMAL
AMAL
BCYC
BCYC
Q4 25
1.6%
1.2%
Q3 25
1.4%
5.7%
Q2 25
0.9%
17.1%
Q1 25
2.3%
6.1%
Q4 24
2.3%
33.3%
Q3 24
0.7%
16.3%
Q2 24
0.3%
4.5%
Q1 24
0.3%
0.1%
Cash Conversion
AMAL
AMAL
BCYC
BCYC
Q4 25
Q3 25
1.47×
Q2 25
0.96×
Q1 25
1.37×
Q4 24
Q3 24
1.28×
Q2 24
1.05×
Q1 24
1.15×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons